A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib (HKI-272) After Trastuzumab In Women With Early-Stage HER-2/Neu Overexpressed/Amplified Breast Cancer

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib (HKI-272) After Trastuzumab In Women With Early-Stage HER-2/Neu Overexpressed/Amplified Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Neratinib (Primary)
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ExteNET
  • Sponsors Pfizer; Puma Biotechnology; Wyeth
  • Most Recent Events

    • 22 Nov 2017 According to a Specialised Therapeutics Asia media release, Arlene Chan is a principal trial investigator.
    • 13 Nov 2017 Results published in the Lancet Oncology
    • 13 Nov 2017 Results from 5-year analysis published in a Puma Biotechnology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top